Stifel analyst Clemence Thiers initiated coverage of Nanobiotix with a Buy rating and EUR 16 price target, implying 304% potential upside to the current share price. NBTXR3, Nanobiotix’s lead asset, is an innovative radioenhancer designed to improve the effectiveness of radiotherapy by amplifying the radiation dose intratumorally, triggering both local and systemic responses, the analyst tells investors in a research note. The firm says the company has an innovative physical-based approach to cancer treatment, which is supported by collaborations with prestigious partners.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix Reveals Promising Cancer Therapy Insights
- NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
- Nanobiotix Updates Share Capital and Voting Rights
- Voting Rights and Shares Capital of the Company
- Nanobiotix’s NBTXR3 Shows Promising Cancer Treatment Results